Request Demo
Last update 09 May 2025
Genakumab
Last update 09 May 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms Firsekibart, Kinnazumab, 伏欣奇拜单抗 + [2] |
Target |
Action inhibitors |
Mechanism IL-1β inhibitors(Interleukin-1 beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 1188682110H
Source: *****
Sequence Code 1188682113L
Source: *****
Related
23
Clinical Trials associated with GenakumabNCT06963177
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain
NCT06451848
A Single Center, Randomized, Double-blind, Single Dose Bioequivalence Trial of Genakumab in Chinese Healthy Male Adults
CTR20242023
金纳单抗在中国健康成年男性受试者中单中心、随机、双盲、单次给药的生物等效性试验
[Translation] A single-center, randomized, double-blind, single-dose bioequivalence study of jinanatumab in healthy Chinese adult male subjects
100 Clinical Results associated with Genakumab
Login to view more data
100 Translational Medicine associated with Genakumab
Login to view more data
100 Patents (Medical) associated with Genakumab
Login to view more data
1
Literatures (Medical) associated with GenakumabJournal of Translational Medicine
Firsekibart in acute gouty arthritis
Letter
Author: Li, Rongbin ; Li, Rongping ; Duan, Xinwang ; Yu, Jing ; Xue, Yu ; Gou, Wei ; Qian, Long ; Li, Juan ; Zou, Hejian ; Duan, Lihua ; Hu, Jiankang ; Zhang, Ning ; Chu, Tianshu
100 Deals associated with Genakumab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Arthritis, Gouty | NDA/BLA | China | 11 Apr 2024 | |
| Systemic onset juvenile chronic arthritis | Phase 3 | China | 12 Jan 2024 | |
| Primary gout | Phase 3 | China | 11 Jan 2023 | |
| Endometriosis | Phase 2 | China | 19 Jun 2025 | |
| Interstitial lung disease due to connective tissue disease | Phase 2 | China | 30 Dec 2023 | |
| Interstitial lung disease due to systemic disease | Phase 2 | China | 30 Dec 2023 | |
| Rheumatoid arthritis with rheumatoid lung disease | Phase 2 | China | 30 Dec 2023 | |
| Still's Disease, Adult-Onset | Phase 1 | United States | 14 Jun 2022 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 07 Jun 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 313 | nvnatrmviy(qoqjawuekp): Difference (Mean) = -3.32 (95% CI, -7.56 to 0.91) View more | Positive | 16 Nov 2024 | |||
Compound betamethasone |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free